DEHOP

AcronymDefinition
DEHOPDartmouth Employee Home Ownership Program (Hanover, NH)
References in periodicals archive ?
Consistent with our development strategy to establish corporate partnerships, we believe the opportunity for DEHOP is greatly strengthened by this clear path forward and the strong evidence of clinical benefit from the completed Phase II study in patients who have failed all other therapies.
Earlier Phase II trials of DEHOP conducted by the Company demonstrated clinical benefit in nearly 80% of the patients, all of whom had failed other anti-diarrheal therapies.
DEHOP is a polyamine analog with both anti-secretory and anti-motility properties, as well as having the potential for anti-proliferative activity.
The Company's lead polyamine analogues are DEHOP for AIDS-related diarrhea, which completed Phase II trials in the fourth quarter of 1997, and DENSPM for cancer, which has begun Phase II trials under the direction of the Parke-Davis Pharmaceutical Research unit of Warner-Lambert Company.
SunPharm's lead polyamine analogues are DEHOP for AIDS-related diarrhea, which completed Phase II trials in the fourth quarter of 1997, and DENSPM for cancer, which is starting Phase II trials under the direction of the Parke- Davis Pharmaceutical Research unit of Warner-Lambert.
The patients were hospitalized for three days prior to DEHOP therapy to establish baseline data and for three days post-therapy to determine drug efficacy on the refractory diarrhea.
In addition, the study confirmed the antidiarrheal effects of DEHOP observed in a Phase I trial.
SunPharm's leading polyamine analogues are DEHOP, which is in Phase II clinical trials for AIDS-related diarrhea and in Phase I clinical trials for cancer, and DENSPM for cancer (Phase I).
The possibility that the unique mechanism of action of DEHOP, one drug in SunPharm's platform of polyamine analogues, may lead to a new treatment for IBD is extremely exciting for the Company.
The IND filing of DEHOP for ulcerative colitis follows two other allowed INDs for the compound.
We are extremely excited about the upcoming Phase I clinical trials for DEHOP in cancer," said Stefan Borg, President and Chief Executive Officer of SunPharm.
In addition to the cancer clinical trial, DEHOP is currently in Phase II clinical trials for chronic AIDS-related diarrhea.